The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia) and one IL-17 inhibitor (Novartis’s Cosentyx). The TNF-α inhibitors are the most widely prescribed biologics in AxSpA patients refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and the growing IL-17 class, which has efficacy data that have met more-stringent clinical trial endpoints. Cimzia was approved by the FDA in March 2019 for nonradiographic (nr)-AxSpA, marking the first FDA approval for that subpopulation. The impending entry of additional IL-17 inhibitors (Eli Lilly’s Taltz, UCB’s bimekizumab, and Kyowa Hakko Kirin’s Lumicef) and the first oral targeted therapy for this indication (Pfizer’s Jak inhibitor Xeljanz) will also shift market dynamics.
- How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
- What are interviewed experts’ insights on current treatment options for ankylosing spondylitis (AS) and nr-AxSpA? What clinical needs remain unfulfilled?
- What pipeline products are the most promising, and what sales / uptake could they secure in AxSpA? What therapies of note are progressing in earlier phases?
- What are the drivers and constraints in the AxSpA market, and how will the market evolve over the forecast period?
Geographies: United States, EU5, Japan
Primary Research: ~30 country-specific interviews with thought-leading rheumatologists; Supported by survey data collected for this and other DRG research
Epidemiology: Diagnosed prevalent cases of axial spondyloarthritis by country, ankylosing spondylitis and nonradiographic axial spondyloarthritis subpopulations
Forecast: 10-year, annualized, drug-level sales and patient share of key axial spondyloarthritis therapies through 2028, segmented by brands/generics and epidemiological subpopulations
Emerging therapies: Phase III/PR: 4 drugs; Phase II: 2 drugs
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.